$Pfizer (PFE.US)$ Pfizer Inc. (NYSE:PFE) secured a $10 billi...
$Pfizer (PFE.US)$ Pfizer Inc. (NYSE:PFE) secured a $10 billion deal to acquire obesity drug developer Metsera, Inc. (NASDAQ:MTSR), beating out Novo Nordisk A/S (NYSE:NVO) after a heated bidding war that captivated Wall Street.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Market Insights
Hot Topics Hot Topics
Trump's 'Taco deal' sparks market rebound : Market rebound sustainable ?
1. If tariffs pause, which sectors benefit first? 2. Trump's "threat-compromise" cycle normalizes—how to hedge across assets?
Moo Options Explorer
Apr 7 17:28
Weekly roundup: Tariff turmoil and recession fears dominate
Moo Options Explorer
Mar 31 17:01
Weekly roundup: Tariff concerns and Tesla’s rollercoaster ride
MonkeyGee : is the drug ready or approved
赢哥 : this incompetent company cannot invent medicine and got no choice but to acquire other companies for their expertise. Will never enter this counter unless it drop to 20 dollar level.
thoughtful Bat_8163 MonkeyGee : Metsera's drug, MET-097i, is not yet FDA approved but is advancing into Phase III trials, which are expected to start in late 2025. Potential FDA approval is projected for 2027 or 2028, following positive Phase IIb results that showed significant weight loss.